Inaccuracies in the recently published review on mirabegron

Por Siddiqui, Emad
Publicado em 2013

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

Por Chapple, Christopher R., Nitti, Victor W., Khullar, Vik, Wyndaele, Jean Jacques, Herschorn, Sender, van Kerrebroeck, Philip, Blauwet, Mary Beth, Siddiqui, Emad
Publicado no World J Urol (2014)

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results...

Por Batista, Jose E., Kölbl, Heinz, Herschorn, Sender, Rechberger, Tomasz, Cambronero, Javier, Halaska, Michael, Coppell, Alex, Kaper, Mathilde, Huang, Moses, Siddiqui, Emad
Publicado no Ther Adv Urol (2015)